| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
484,602 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,100,996 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
70 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siegall Clay B |
President and CEO |
• • – |
2013-01-02 |
4 |
OE |
$3.30 |
$20,622 |
D/D |
6,249 |
1,177,210 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2012-12-17 |
4 |
AS |
$23.70 |
$1,184,955 |
D/D |
(50,000) |
113,829 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2012-12-17 |
4 |
OE |
$10.20 |
$681,573 |
D/D |
62,418 |
163,829 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-10 |
4 |
S |
$25.75 |
$169,641 |
D/D |
(6,588) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-10 |
4 |
OE |
$10.29 |
$72,061 |
D/D |
6,588 |
62,939 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-07 |
4 |
S |
$25.77 |
$773,082 |
D/D |
(30,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-07 |
4 |
OE |
$10.29 |
$308,700 |
D/D |
30,000 |
87,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-06 |
4 |
S |
$25.77 |
$772,983 |
D/D |
(30,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-06 |
4 |
OE |
$12.16 |
$364,800 |
D/D |
30,000 |
87,601 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2012-12-05 |
4 |
S |
$25.54 |
$1,723,950 |
D/D |
(67,500) |
117,950 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2012-12-05 |
4 |
OE |
$3.50 |
$461,325 |
D/D |
67,500 |
125,450 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-05 |
4 |
S |
$25.60 |
$256,000 |
D/D |
(10,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-05 |
4 |
OE |
$12.16 |
$121,600 |
D/D |
10,000 |
67,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-04 |
4 |
S |
$25.45 |
$767,500 |
D/D |
(30,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-04 |
4 |
OE |
$12.00 |
$363,200 |
D/D |
30,000 |
67,601 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2012-12-03 |
4 |
OE |
$8.38 |
$26,137 |
D/D |
3,119 |
6,119 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2012-12-03 |
4 |
AS |
$25.19 |
$207,777 |
D/D |
(8,250) |
1,170,961 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2012-12-03 |
4 |
OE |
$3.30 |
$27,225 |
D/D |
8,250 |
1,179,211 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-03 |
4 |
S |
$25.45 |
$254,500 |
D/D |
(10,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-12-03 |
4 |
OE |
$12.16 |
$121,600 |
D/D |
10,000 |
67,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-11-30 |
4 |
S |
$25.50 |
$255,000 |
D/D |
(10,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-11-30 |
4 |
OE |
$12.00 |
$120,084 |
D/D |
10,000 |
58,124 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-11-29 |
4 |
S |
$25.25 |
$507,085 |
D/D |
(20,000) |
57,601 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-11-29 |
4 |
OE |
$12.00 |
$240,000 |
D/D |
20,000 |
57,926 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2012-11-26 |
4 |
S |
$25.50 |
$76,500 |
D/D |
(3,000) |
57,601 |
|
- |
|
1805 Records found
|
|
Page 44 of 73 |
|
|
